Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine

Journal of Infectious Diseases

Volumn 190, Issue 2, 2004, Pages 409-416

  Martinez, Claudia V ^a,b   Old, Matt O ^a,c   Kwock, Douglas K ^a,d   Khan, Shalla S ^a,e   Garcia, Joaquin J ^a   Chan, Christina S ^a,f   Webster, Ramothea ^a,b   Falkovitz Halpern, Meira S ^a   Maldonado, Yvonne A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e TOURO UNIVERSITY CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; ORAL POLIOMYELITIS VACCINE; RESTRICTION ENDONUCLEASE; URACIL;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; GASTROINTESTINAL TRACT; HUMAN; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION MAPPING; RNA EXTRACTION; VACCINATION; VACCINATION REACTION; VIRUS MUTANT;

BASE SEQUENCE; FECES; FEMALE; HUMANS; INFANT; MALE; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SELECTION (GENETICS); VIRULENCE; VIRUS SHEDDING;

EID: 3242730051     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/421703     Document Type: Article

References (49)

1. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine: effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960; 173:1521-6.
2. Kim-Farley RJ, Bart KJ, Schonberger LB, et al. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus. Lancet 1984; 2: 1315-7.
3. Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. The susceptibility of young adult Americans to vaccine-preventable infections: a national serosurvey of US army recruits. JAMA 1991; 266:2724-9.
4. Melnick JL. Advantages and disadvantages of killed and live polio-myelitis vaccines. Bull World Health Organ 1978; 56:21-38.
5. Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention: revised recommendations for routine poliomyelitis vaccination. JAMA 1999; 282:522.
6. Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention: recommended childhood immunization schedule - United States, 1999. JAMA 1999; 281:601-3.
7. Zimmerman RK, Spann SJ. Poliovirus vaccine options. Am Fam Physician 1999; 59:113-8, 125-6.
8. Cann AJ, Stanway G, Hughes PJ, et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res 1984; 12:7787-92.
9. Georgescu MM, Balanant J, Macadam A, et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 1997; 71:7758-68.
10. Guillot S, Otelea D, Delpeyroux F, Crainic R. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 1994; 12:503-7.
11. Kawamura N, Kohara M, Abe S, et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 1989; 63:1302-9.
12. Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 1991; 65:1377-82.
13. Svitkin YV, Pestova TV, Maslova SV, Agol VI. Point mutations modify the response of poliovirus RNA to a translation initiation factor: a comparison of neurovirulent and attenuated strains. Virology 1988; 166:394-404.
14. Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 1989; 63:1338-4.
15. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14:568-79.
16. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49(RR-05):1-22.
17. Friedrich F. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus. Acta Virol 2000; 44:109-17.
18. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 1994; 148:479-85.
19. Chang TW, Weinstein L, MacMahon HE. Paralytic poliomyelitis in a child with hypogammaglobulinemia: probable implication of type I vaccine strain. Pediatrics 1966; 37:630-6.
20. Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol 1981; 56:337-47.
21. Evans DM, Dunn G, Minor PD, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 1985; 314:548-50.
22. Minor PD, Dunn G. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J Gen Virol 1988; 69:1091-6.
23. Chumakov KM, Dragunsky EM, Norwood LP, et al. Consistent selection of mutations in the 5′-untranslated region of oral poliovirus vaccine upon passaging in vitro. J Med Virol 1994; 42:79-85.
24. Old MO, Martinez CV, Kwock D, et al. Direct extraction of Sabin poliovirus genomes from human fecal samples using a novel guanidine thiocyanate extraction method. J Virol Methods 2003; 110:193-200.
25. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 1991; 88:199-203.
26. Chumakov K. Mutant analysis by PCR and restriction enzyme cleavage (MAPREC) for oral poliovirus (Sabin) vaccine: standard operating procedure. World Health Organization (WHO) Collaborative Study on MAPREC. Vol. 3.4. Geneva: WHO, 2000:1-27.
27. Chumakov K, Norwood L, Parker M, et al. Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Dev Biol Stand 1993; 78:79-89; discussion 88-9.
28. De L, Nottay B, Yang CF, Holloway BP, Pallansch M, Kew O. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J Clin Microbiol 1995; 33:562-71.
29. Maldonado Y, Cantwell M, Old M, et al. Population-based prevalence of symptomatic and asymptomatic astrovirus infection in rural Mayan infants. J Infect Dis 1998; 178:334-9.
30. Maldonado YA, Pena-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis 1997; 175:545-53.
31. Boom R, Sol C, Beld M, Weel J, Goudsmit J, Wertheim-van Dillen P. Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine α-casein to silica particles. J Clin Microbiol 1999; 37:615-9.
32. Boom R, Sol C, Weel J, et al. Detection and quantitation of human cytomegalovirus DNA in faeces. J Virol Methods 2000; 84:1-14.
33. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa I. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
34. Stanway G, Cann AJ, Hauptmann R, et al. The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1. Nucleic Acids Res 1983; 11:5629-43.
35. Lu Z, Douthitt MP, Taffs RE, Ran Y, Norwood LP, Chumakov KM. Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC). PCR Methods Appl 1993; 3:176-80.
36. Rabenau HF, Clarici AM, Muhlbauer G, et al. Rapid detection of enterovirus infection by automated RNA extraction and real-time fluorescence PCR. J Clin Virol 2002; 25:155-64.
37. Landry ML, Garner R, Ferguson D. Rapid enterovirus RNA detection in clinical specimens by using nucleic acid sequence-based amplification. J Clin Microbiol 2003; 41:346-50.
38. Schwerdt CE, Fogh J. The ratio of physical particles per infectious unit observed for poliomyelitis virus. Virology 1957; 4:590-3.
39. Joklik WK, Darnell JE. The adsorption and early fate of purified poliovirus in HeLa cells. Virology 1961; 13:439-47.
40. Dunn G, Begg NT, Cammack N, Minor PD. Virus excretion and mutation by infants following primary vaccination with live oral polio-vaccine from two sources. J Med Virol 1990; 32:92-5.
41. Ogra PL. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines. Ann NY Acad Sci 1995; 754:97-107.
42. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993; 168: 1105-9.
43. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD. Effect of prior immunity on the shedding of virulent revenant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991; 164:191-4.
44. Buonagurio DA, Coleman JW, Patibandla SA, Prabhakar BS, Tatem JM. Direct detection of Sabin poliovirus vaccine strains in stool specimens of first-dose vaccinees by a sensitive reverse transcription-PCR method. J Clin Microbiol 1999; 37:283-9.
45. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA 1996; 93:2370-5.
46. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 1999; 73:958-64.
47. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of polio-myelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9.
48. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 2002; 83:1107-11.
49. Horie H, Yoshida H, Matsuura K, et al. Neurovirulence of type 1 polioviruses isolated from sewage in Japan. Appl Environ Microbiol 2002; 68: 138-42.